-
Mashup Score: 57
PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)–based prophylaxis. METHODS Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. RESULTS Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syn
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57
PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)–based prophylaxis. METHODS Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. RESULTS Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syn
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
This is extremely important work supported by @nmdp_org and @CIBMTR. Use of MMUD with PTCy truly means there are donors for all! | PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors https://t.co/9DyU63KJly https://t.co/4W4JCZqCvd
-
-
Mashup Score: 0
PostAaron Logan, MD, PhD, MPhil@hemedoc#tandem24 #bmtsm Cutler: Signif lower incidence of steroid requiring cGVHD in the Obi arm. No impact on incidence of overall cGVHD, relapse, or TRM.9:24 PM · Feb 22, 2024207 Views1 Quote1 LikeNew to X?Sign up now to get your own personalized timeline!Sign up with AppleCreate accountBy signing up, you agree to the Terms of Service and Privacy Policy,…
Source: x.comCategories: General Medicine News, Hem/OncsTweet-
@timfenske https://t.co/Xra6n2pq5H
-
-
Mashup Score: 9Building a Community of Hope | INTO HLH Registry - 11 month(s) ago
The Registry is aimed at advancing what is known about HLH and will help doctors to better diagnose and manage HLH and improve treatment outcomes for future patients
Source: hlhregistry.orgCategories: General Medicine News, Hem/OncsTweet-
#tandem24 Jordan: https://t.co/sz3MTE3VA2 recruiting patients of all ages and all types of HLH to better understand the syndrome. Patients can self-consent on the site. 🆒
-
-
Mashup Score: 3Maui Strong Fund - 1 year(s) ago
Maui Strong
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @MazieTsangMD: Resources for #MauiFires Please donate to: https://t.co/NIwRCIZAIo @HCFHawaii donates 100% of proceeds to local non-pr…
-
-
Mashup Score: 38Sign the Petition - 1 year(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
It’s nice to see so many others rallying around elimination of ABIM’s cartel-like behavior and extortion via MOC fees. I signed the petition, of course. Kudos to @AaronGoodman33 for rolling this out. Next step is to get press coverage to spread the word. https://t.co/UU7JIFhXeX https://t.co/z0YoGE9o2Y
-
-
Mashup Score: 2curate.ai - Domain Name For Sale | Dan.com - 2 year(s) ago
I found a great domain name for sale on Dan.com. Check it out!
Source: DAN.COMCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO23 #ai #aimedsm Ho: Developing a digital avatar for a pt would implement #deeplearning to make decisions for optimal tx for a pt. Right drug at right time is another dimension beyond right regime for right dx. https://t.co/cy84jMiETX a digital avatar tool in development. https://t.co/CUyAkIrEZQ
-
-
Mashup Score: 0Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis - 2 year(s) ago
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of severe, dysregulated inflammation driven by the inability of T cells to clear an antigenic target. When associated with malignancy (mHLH), the HLH syndrome is typically associated with extremely poor survival. Here, we review the diagnosis of secondary HLH (sHLH) syndromes in adults, with emphasis on the appropriate workup and treatment of…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Jerry Lee @TheBloodDoc and I are pleased to share this guide for diagnosis and management of adult malignancy-associated hemophagocytic lymphohistiocytosis (#HLH), pub'd 3/18/23 https://t.co/OdBHH58PdF #mdpicancers via @Cancers_MDPI
-
-
Mashup Score: 0
Ravi B. Parikh, MD, MPP, explores the evidence-based oncology movement, which started off promising but transformed into takedowns of trials, investigators, and the FDA.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet-
This * 💯,000,000! Must read piece by @ravi_b_parikh. 👏🏻 Why Evidence-Based Medicine Fans Could Use a Lesson in Persuasion https://t.co/ZjXX1nZb3y via @medscape
-
-
Mashup Score: 0News Releases | Talaris Therapeutics, Inc. - 2 year(s) ago
The Investor Relations website contains information about Talaris Therapeutics, Inc.’s business for stockholders, potential investors, and financial analysts.
Source: Talaris Therapeutics Inc.Categories: Hem/Oncs, Latest HeadlinesTweet-
We’ve been working quite hard to open the @TalarisTx Freedom-1 trial for combined allo kidney/HCT for tolerance induction. Sad to see just now the protocol is being abandoned… :( https://t.co/DSrV6bzPtD
-
This is extremely important work supported by @nmdp_org and @CIBMTR. Use of MMUD with PTCy truly means there are donors for all! | PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors https://t.co/9DyU63KJly https://t.co/4W4JCZqCvd